What is the difference between Aniracetam and Unifiram?

Aniracetam: Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European ... Unifiram: Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Floren...

What does the research say about Aniracetam vs Unifiram?

Aniracetam: The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No… Unifiram: No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine,…

Aniracetam vs Unifiram

Q: Can you stack Aniracetam and Unifiram?

Aniracetam (cognitive) and Unifiram (cognitive) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of Aniracetam and Unifiram — mechanism, side effects, legal status, and pricing.

Aniracetam

Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European countries (Italy, Greece) but has never been approved by the US FDA as either a drug or dietary supplement ingredient. The compound was reportedly withdrawn from the Japanese market following a failed confirmatory trial. Despite lacking US regulatory approval, aniracetam is openly sold online by nootropic-supplement retailers, often with significant label-accuracy problems.

Profile Prices Testing

Unifiram

Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.

Profile Prices Testing

Aniracetam

Unifiram

Category

Cognitive

Legal Status

Research Only

Mechanism

Aniracetam is a positive allosteric modulator of AMPA-type ionotropic glutamate receptors. X-ray crystallographic and electrophysiological work on the GluA2 ligand-binding domain demonstrates that aniracetam binds at the dimer interface, on the twofold axis of molecular symmetry, adjacent to the hinge of the clamshell-like ligand-binding core. This binding stabilizes the closed-cleft, glutamate-bound conformation and slows receptor deactivation and desensitization, a mechanism distinct from piracetam's binding site.

Preclinical evidence indicates unifiram facilitates AMPA-receptor-mediated neurotransmission without direct receptor binding: in rat hippocampal slices it increased fEPSP amplitude and reversed kynurenic-acid antagonism of NMDA-mediated transmitter release, effects blocked by the AMPA-receptor antagonist NBQX. It also increased acetylcholine release from rat cerebral cortex, suggesting an additional cholinergic component. Radioligand binding assays showed no significant affinity for major central receptors or ion channels, so the specific molecular binding site remains unidentified.

Side Effects

Tolerability reported as 'excellent' in one 6-month trial, but no itemized adverse-event data available
No long-term (multi-year) human safety data located
Regulatory withdrawal in Japan following failed confirmatory trial suggests inconsistent efficacy/safety signal

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

Aniracetam

No pricing data yet.

Check Aniracetam prices →

Unifiram

Best $/mg

$0.032/mg

Kimera ChemsC

1 trusted vendor listing

Compare all 1 vendor

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

Aniracetam

COAs

99.5%

Avg purity

Labs

Full testing data

Unifiram

COAs

99.4%

Avg purity

Labs

Full testing data

Aniracetam Research Summary

The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No long-term (multi-year) human safety data were located, and no interventional trials of aniracetam are currently registered on ClinicalTrials.gov. In rodent models, aniracetam (50 mg/kg/day for 10 postnatal days) reversed prenatal-ethanol-induced avoidance-learning deficits in rat offspring and increased AMPA-receptor-mediated synaptic currents in hippocampal CA1 pyramidal cells. However, oral aniracetam (50 mg/kg, 5 days/week for 6 weeks) produced no cognitive or behavioral enhancement in healthy adult C57BL/6J mice across a comprehensive test battery.

Key references

Unifiram Research Summary

No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.

Key references

Can you stack Aniracetam and Unifiram?

Aniracetam and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

Aniracetam vs Piracetam Piracetam vs Unifiram Aniracetam vs Oxiracetam Aniracetam vs Pramiracetam Aniracetam vs Nefiracetam Aniracetam vs Coluracetam Aniracetam vs Fasoracetam Aniracetam vs Phenylpiracetam hydrazide

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.